Irreverent Genetics

At Merck, Eric Schadt takes an iconoclastic approach to drug discovery - and dressing.

Written byBob Grant
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Eric Schadt doesn't care much about how he dresses. In fact, the executive scientific director of research genetics at Rosetta Inpharmatics has about 20 or 30 identical white polo shirts and about 10 pairs of identical khaki shorts hanging in his closet. He dons this recurring outfit - over white socks and Birkenstock sandals - every day before heading to work at Rosetta, a wholly-owned subsidiary of Merck.

The 43-year-old says he has more important things to concentrate on than fashion - like using expression microarrays to construct complex gene interaction networks which identify novel targets to treat diseases. "What I have to do every day is push super hard on the thinking front and on the doing front," he says. "It's much easier to push and think hard if you don't have to think about other things that don't matter so much."

Schadt has been championing the importance of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies